News Image

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Provided By GlobeNewswire

Last update: Jan 10, 2025

Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione

Read more at globenewswire.com

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (6/11/2025, 4:30:00 PM)

After market: 32.33 0 (0%)

32.33

-0.75 (-2.27%)



Find more stocks in the Stock Screener

Follow ChartMill for more